Logo image of INVO

INVO BIOSCIENCE INC (INVO) Stock Fundamental Analysis

NASDAQ:INVO - Nasdaq - US44984F4019 - Common Stock - Currency: USD

0.833  -0.03 (-2.91%)

After market: 0.825 -0.01 (-0.96%)

Fundamental Rating

2

Taking everything into account, INVO scores 2 out of 10 in our fundamental rating. INVO was compared to 189 industry peers in the Health Care Equipment & Supplies industry. INVO has a bad profitability rating. Also its financial health evaluation is rather negative. INVO shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year INVO has reported negative net income.
In the past year INVO has reported a negative cash flow from operations.
INVO had negative earnings in each of the past 5 years.
INVO had negative operating cash flow in 4 of the past 5 years.
INVO Yearly Net Income VS EBIT VS OCF VS FCFINVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2M -4M -6M -8M -10M

1.2 Ratios

INVO has a Return On Assets of -39.30%. This is in the lower half of the industry: INVO underperforms 61.70% of its industry peers.
INVO has a worse Return On Equity (-519.72%) than 88.30% of its industry peers.
Industry RankSector Rank
ROA -39.3%
ROE -519.72%
ROIC N/A
ROA(3y)-122.53%
ROA(5y)-112.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INVO Yearly ROA, ROE, ROICINVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K

1.3 Margins

Looking at the Gross Margin, with a value of 44.86%, INVO is doing worse than 62.23% of the companies in the same industry.
INVO's Gross Margin has declined in the last couple of years.
INVO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-26.71%
GM growth 5Y-15.12%
INVO Yearly Profit, Operating, Gross MarginsINVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K -40K

More info and screens

0

2. Health

2.1 Basic Checks

INVO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for INVO has been increased compared to 1 year ago.
The number of shares outstanding for INVO has been increased compared to 5 years ago.
The debt/assets ratio for INVO has been reduced compared to a year ago.
INVO Yearly Shares OutstandingINVO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M
INVO Yearly Total Debt VS Total AssetsINVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -5.70, we must say that INVO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of INVO (-5.70) is worse than 70.74% of its industry peers.
INVO has a Debt/Equity ratio of 1.51. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.51, INVO is not doing good in the industry: 82.45% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.51
Debt/FCF N/A
Altman-Z -5.7
ROIC/WACCN/A
WACC7.27%
INVO Yearly LT Debt VS Equity VS FCFINVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M 4M -4M 6M -6M

2.3 Liquidity

INVO has a Current Ratio of 0.30. This is a bad value and indicates that INVO is not financially healthy enough and could expect problems in meeting its short term obligations.
INVO's Current ratio of 0.30 is on the low side compared to the rest of the industry. INVO is outperformed by 94.68% of its industry peers.
A Quick Ratio of 0.27 indicates that INVO may have some problems paying its short term obligations.
INVO's Quick ratio of 0.27 is on the low side compared to the rest of the industry. INVO is outperformed by 95.21% of its industry peers.
Industry RankSector Rank
Current Ratio 0.3
Quick Ratio 0.27
INVO Yearly Current Assets VS Current LiabilitesINVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 79.65% over the past year.
INVO shows a strong growth in Revenue. In the last year, the Revenue has grown by 384.42%.
Measured over the past years, INVO shows a very strong growth in Revenue. The Revenue has been growing by 43.87% on average per year.
EPS 1Y (TTM)79.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.67%
Revenue 1Y (TTM)384.42%
Revenue growth 3Y42.68%
Revenue growth 5Y43.87%
Sales Q2Q%473.94%

3.2 Future

Based on estimates for the next years, INVO will show a very strong growth in Earnings Per Share. The EPS will grow by 41.42% on average per year.
Based on estimates for the next years, INVO will show a very strong growth in Revenue. The Revenue will grow by 101.26% on average per year.
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year199.65%
Revenue Next 2Y172.81%
Revenue Next 3Y152.43%
Revenue Next 5Y101.26%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
INVO Yearly Revenue VS EstimatesINVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M
INVO Yearly EPS VS EstimatesINVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 -5 -10 -15 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INVO. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INVO Price Earnings VS Forward Price EarningsINVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INVO Per share dataINVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

INVO's earnings are expected to grow with 41.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INVO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INVO BIOSCIENCE INC

NASDAQ:INVO (10/21/2024, 8:21:24 PM)

After market: 0.825 -0.01 (-0.96%)

0.833

-0.03 (-2.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2024-08-12/amc
Earnings (Next)11-11 2024-11-11/amc
Inst Owners7.01%
Inst Owner Change-75.78%
Ins Owners9.11%
Ins Owner Change0%
Market Cap3.26M
Analysts43.33
Price Target20.4 (2348.98%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.57
P/FCF N/A
P/OCF N/A
P/B 2.39
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.24
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-1.02
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS1.47
BVpS0.35
TBVpS-2.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.3%
ROE -519.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.86%
FCFM N/A
ROA(3y)-122.53%
ROA(5y)-112.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-26.71%
GM growth 5Y-15.12%
F-Score4
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 1.51
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.84%
Cap/Sales 5.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.3
Quick Ratio 0.27
Altman-Z -5.7
F-Score4
WACC7.27%
ROIC/WACCN/A
Cap/Depr(3y)577.96%
Cap/Depr(5y)746.78%
Cap/Sales(3y)8.92%
Cap/Sales(5y)8.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.67%
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)384.42%
Revenue growth 3Y42.68%
Revenue growth 5Y43.87%
Sales Q2Q%473.94%
Revenue Next Year199.65%
Revenue Next 2Y172.81%
Revenue Next 3Y152.43%
Revenue Next 5Y101.26%
EBIT growth 1Y45.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y46.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.93%
OCF growth 3YN/A
OCF growth 5YN/A